The short answer
An aluminum-containing antacid needs a timing review with oral cefuroxime axetil. Its prescribing information directs the antibiotic at least one hour before or two hours after a short-acting antacid. This does not establish an interaction with every aluminum exposure or with injected cefuroxime.
What this answer covers
Oral cefuroxime axetil and aluminum-containing antacids such as aluminum hydroxide. Elemental aluminum, ordinary environmental exposure and parenteral cefuroxime are outside the absorption precaution.
- Supplement or preparation
- Aluminum
- Medication ingredient
- cefuroxime
Which aluminum product is relevant?
The concern is a swallowed antacid, particularly an aluminum hydroxide preparation that neutralizes stomach acid. The generic mineral name is broader than that use. It should not be read as a warning about metal contact, packaging or all trace aluminum in foods.
How should the doses be spaced?
Follow the oral cefuroxime-axetil label: take the antibiotic at least one hour before, or at least two hours after, a short-acting antacid. The direction matters. Ask the pharmacist to confirm the schedule when the antacid combines aluminum and magnesium or is used repeatedly.
Does every study show reduced exposure?
No. A small study in seven peritoneal-dialysis patients found similar cefuroxime exposure with and without a phosphate binder. Aluminum hydroxide appears in its indexing, but the accessible abstract does not identify the exact binder or dose. That negative result is retained without treating it as proof for every antacid regimen.
Does this also apply to an injection?
The gastric-acidity warning concerns absorption of the oral axetil prodrug. An injected cefuroxime product bypasses that step. The sources do not justify transferring this timing rule to an injection or claiming that aluminum necessarily makes every cefuroxime course fail.
Evidence and practical considerations
Absorption & effectiveness
An aluminum-containing antacid needs a timing review with oral cefuroxime axetil. Its prescribing information directs the antibiotic at least one hour before or two hours after a short-acting antacid. This does not establish an interaction with every aluminum exposure or with injected cefuroxime.
- Exact scope
- Oral cefuroxime axetil and aluminum-containing antacids such as aluminum hydroxide. Elemental aluminum, ordinary environmental exposure and parenteral cefuroxime are outside the absorption precaution. with oral cefuroxime axetil, converted to cefuroxime; not injected cefuroxime sodium
- Medication form and route
- oral
- Timing or duration
- During co-use; study-specific durations are retained in the source summaries. No universal duration or dose-response inferred.
What remains uncertain
- Class-level oral-antacid precaution with no verified preparation-specific effect size. Small contrary binder study has unresolved binder identity and a special renal population.
Factors that may matter: exact supplement preparation and dose; oral versus nonoral medication route; other formula ingredients; gastric-acidity effect and concurrent treatment.
Read the supporting source summaries
Source 1: regulatory product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People receiving oral cefuroxime axetil tablets.
Reduced stomach acidity can lower oral bioavailability. Administer antibiotic at least one hour before or two hours after short-acting antacids. Label also warns about C. difficile-associated diarrhea.
How this applies: RxCUI 2194 active cefuroxime is reached after oral axetil conversion. Gastric-pH effect is restricted to oral axetil, not injected cefuroxime sodium. Exact package scope: Oral cefuroxime axetil and aluminum-containing antacids such as aluminum hydroxide. Elemental aluminum, ordinary environmental exposure and parenteral cefuroxime are outside the absorption precaution.
Antacid class precaution does not quantify the effect of every mineral salt; tablets and suspension are not interchangeable milligram for milligram.
Source 2: government drug-identity reference
cancer.gov · Source check Sep 10, 2026
Population: Users of oral aluminum hydroxide and magnesium hydroxide suspension.
Identifies these hydroxides as acid-neutralizing antacid ingredients.
How this applies: Supports applying an antacid-class precaution to these acid-neutralizing preparations, not to all aluminum or magnesium exposures. Exact package scope: Oral cefuroxime axetil and aluminum-containing antacids such as aluminum hydroxide. Elemental aluminum, ordinary environmental exposure and parenteral cefuroxime are outside the absorption precaution.
No clinical cefuroxime data or isolated ingredient effect size.
Source 3: human crossover pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Seven continuous ambulatory peritoneal dialysis patients without recent peritonitis.
Median peak levels were 22.7 versus 23.2 mg/L and exposure 364 versus 368 mg h/L; no difference in bioavailability was detected.
How this applies: Contrary evidence for an oral cefuroxime/binder interaction. Not proof that every aluminum antacid or regimen is free of effect. Exact package scope: Oral cefuroxime axetil and aluminum-containing antacids such as aluminum hydroxide. Elemental aluminum, ordinary environmental exposure and parenteral cefuroxime are outside the absorption precaution.
Abstract does not identify binder formulation or dose; indexing includes aluminum hydroxide but does not resolve the regimen. Small special population with prolonged cefuroxime half-life.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Replaces broad separate-or-avoid aluminum wording with the oral antacid interval and explicitly retains contrary phosphate-binder evidence. | |
| Research summary published |
Article revision: b6a3c69302a753f4
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.